GR-203040 HCl |168398-02-5 | NK1 receptor antagonist

MedKoo Cat#: 330127 | Name: GR-203040 HCl

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

GR-203040 is a selective NK1 receptor antagonist. GR203040 inhibits cyclophosphamide-induced damage in the rat and ferret bladder. GR203040 is a novel anti-emetic agent, and the broad spectrum of anti-emetic activity, together with activity observed in three species, suggests that this compound is worthy of clinical investigation.

Chemical Structure

GR-203040 HCl

CAS#168398-02-5 (2HCl)

Theoretical Analysis

MedKoo Cat#: 330127

Name: GR-203040 HCl

CAS#: 168398-02-5 (2HCl)

Chemical Formula: C20H26Cl2N6O

Exact Mass: 0.0000

Molecular Weight: 437.37

Elemental Analysis: C, 54.92; H, 5.99; Cl, 16.21; N, 19.22; O, 3.66

Price and Availability

Size	Price	Availability	Quantity
5mg	USD 350.00	2 Weeks
25mg	USD 950.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

168398-02-5 (2HCl) 780014-53-1 (free base)

Synonym

GR-203040; GR 203040; GR203040; GR-203040 HCl; GR-203040 hydrochloride; GR-203040 dihydrochloride

IUPAC/Chemical Name

(2S,3S)-N-[[2-Methoxy-5-(1H-tetrazol-1-yl)phenyl]methyl]-2-phenyl-3-piperidinamine dihydrochloride

InChi Key

UYDCUPIPQXAELR-OINVMNEBSA-N

InChi Code

InChI=1S/C20H24N6O.2ClH/c1-27-19-10-9-17(26-14-23-24-25-26)12-16(19)13-22-18-8-5-11-21-20(18)15-6-3-2-4-7-15;;/h2-4,6-7,9-10,12,14,18,20-22H,5,8,11,13H2,1H3;2*1H/t18-,20-;;/m0../s1

SMILES Code

COC1=C(CN[C@H]2CCCN[C@H]2C3=CC=CC=C3)C=C(N4C=NN=N4)C=C1.Cl.Cl

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Instruction

View handling instruction

Biological target:

Potent and selective NK1 antagonist.

In vitro activity:

TBD

In vivo activity:

GR203040 (0.1 mg kg-1 s.c.) retains anti-emetic efficacy in the ferret, even when given as a 6 h pretreatment, indicating that this compound has a long duration of action. The compound is also effective orally at the same dose, when given as a 90 min pretreatment. GR203040 is effective against motion- and cisplatin-induced emesis in Suncus murinus. These effects were seen at doses an order of magnitude greater than those shown to be effective against cisplatin in the ferret. In conclusion, GR203040 is a novel anti-emetic agent, and the broad spectrum of anti-emetic activity, together with activity observed in three species. Reference: Br J Pharmacol. 1995 Dec;116(8):3158-63. https://pubmed.ncbi.nlm.nih.gov/8719790/

	Solvent	mg/mL	mM
Solubility
	Water	8.8	20.00

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 437.37 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Gardner CJ, Twissell DJ, Dale TJ, Gale JD, Jordan CC, Kilpatrick GJ, Bountra C, Ward P. The broad-spectrum anti-emetic activity of the novel non-peptide tachykinin NK1 receptor antagonist GR203040. Br J Pharmacol. 1995 Dec;116(8):3158-63. doi: 10.1111/j.1476-5381.1995.tb15118.x. PMID: 8719790; PMCID: PMC1909155. 2. Beattie DT, Beresford IJ, Connor HE, Marshall FH, Hawcock AB, Hagan RM, Bowers J, Birch PJ, Ward P. The pharmacology of GR203040, a novel, potent and selective non-peptide tachykinin NK1 receptor antagonist. Br J Pharmacol. 1995 Dec;116(8):3149-57. doi: 10.1111/j.1476-5381.1995.tb15117.x. PMID: 8719789; PMCID: PMC1909174.

In vitro protocol:

TBD

In vivo protocol:

1: Gallantine EL, Meert TF. Attenuation of the gerbil writhing response by mu-, kappa- and delta-opioids, and NK-1, -2 and -3 receptor antagonists. Pharmacol Biochem Behav. 2004 Sep;79(1):125-35. PubMed PMID: 15388292. 2: Bergström M, Fasth KJ, Kilpatrick G, Ward P, Cable KM, Wipperman MD, Sutherland DR, Långström B. Brain uptake and receptor binding of two [11C]labelled selective high affinity NK1-antagonists, GR203040 and GR205171--PET studies in rhesus monkey. Neuropharmacology. 2000 Feb 14;39(4):664-70. PubMed PMID: 10728887. 3: Alfieri AB, Gardner CJ. Effects of GR203040, an NK1 antagonist, on radiation- and cisplatin-induced tissue damage in the ferret. Gen Pharmacol. 1998 Nov;31(5):741-6. PubMed PMID: 9809472. 4: Alfieri A, Gardner C. The NK1 antagonist GR203040 inhibits cyclophosphamide-induced damage in the rat and ferret bladder. Gen Pharmacol. 1997 Aug;29(2):245-50. PubMed PMID: 9251907. 5: Gardner CJ, Armour DR, Beattie DT, Gale JD, Hawcock AB, Kilpatrick GJ, Twissell DJ, Ward P. GR205171: a novel antagonist with high affinity for the tachykinin NK1 receptor, and potent broad-spectrum anti-emetic activity. Regul Pept. 1996 Aug 27;65(1):45-53. PubMed PMID: 8876035. 6: Ward P, Armour DR, Bays DE, Evans B, Giblin GM, Heron N, Hubbard T, Liang K, Middlemiss D, Mordaunt J, et al. Discovery of an orally bioavailable NK1 receptor antagonist, (2S,3S)-(2-methoxy-5-tetrazol-1-ylbenzyl)(2-phenylpiperidin-3-yl)amine (GR203040), with potent antiemetic activity. J Med Chem. 1995 Dec 22;38(26):4985-92. PubMed PMID: 8544174. 7: Gardner CJ, Twissell DJ, Dale TJ, Gale JD, Jordan CC, Kilpatrick GJ, Bountra C, Ward P. The broad-spectrum anti-emetic activity of the novel non-peptide tachykinin NK1 receptor antagonist GR203040. Br J Pharmacol. 1995 Dec;116(8):3158-63. PubMed PMID: 8719790; PubMed Central PMCID: PMC1909155. 8: Beattie DT, Beresford IJ, Connor HE, Marshall FH, Hawcock AB, Hagan RM, Bowers J, Birch PJ, Ward P. The pharmacology of GR203040, a novel, potent and selective non-peptide tachykinin NK1 receptor antagonist. Br J Pharmacol. 1995 Dec;116(8):3149-57. PubMed PMID: 8719789; PubMed Central PMCID: PMC1909174.